[Skip to Content]
[Skip to Content Landing]
August 1, 2001

Atorvastatin for Acute Coronary Syndromes

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(5):532-535. doi:10.1001/jama.286.5.532

To the Editor: We would like to comment on several points raised by Dr Sacks in his Editorial1 accompanying our report of the MIRACL study.2 The findings of the MIRACL study demonstrated that short-term, intensive lipid-lowering therapy reduces recurrent ischemic cardiovascular events in patients after ACS. We chose 80 mg/d of atorvastatin, the highest approved dosage with the greatest lipid-lowering effects, to maximize the likelihood of observing a benefit of treatment. We agree with Sacks that it remains to be determined if a lower dose of atorvastatin and/or other statins would have similar effects.